1 6569 152 TRANSPLANTATION OF EPIGENETICALLY MODIFIED ADULT CARDIAC C-KIT+ CELLS RETARDS REMODELING AND IMPROVES CARDIAC FUNCTION IN ISCHEMIC HEART FAILURE MODEL. CARDIAC C-KIT+ CELLS HAVE A MODEST CARDIOGENIC POTENTIAL THAT COULD LIMIT THEIR EFFICACY IN HEART DISEASE TREATMENT. THE PRESENT STUDY WAS DESIGNED TO AUGMENT THE CARDIOGENIC POTENTIAL OF CARDIAC C-KIT+ CELLS THROUGH CLASS I HISTONE DEACETYLASE (HDAC) INHIBITION AND EVALUATE THEIR THERAPEUTIC POTENCY IN THE CHRONIC HEART FAILURE (CHF) ANIMAL MODEL. MYOCARDIAL INFARCTION (MI) WAS CREATED BY CORONARY ARTERY OCCLUSION IN RATS. C-KIT+ CELLS WERE TREATED WITH MOCETINOSTAT (MOCE), A SPECIFIC CLASS I HDAC INHIBITOR. AT 3 WEEKS AFTER MI, CHF ANIMALS WERE RETROGRADELY INFUSED WITH UNTREATED (CONTROL) OR MOCE-TREATED C-KIT+ CELLS (MOCE/C-KIT+ CELLS) AND EVALUATED AT 3 WEEKS AFTER CELL INFUSION. WE FOUND THAT CLASS I HDAC INHIBITION IN C-KIT+ CELLS ELEVATED THE LEVEL OF ACETYLATED HISTONE H3 (ACH3) AND INCREASED ACH3 LEVELS IN THE PROMOTER REGIONS OF PLURIPOTENT AND CARDIAC-SPECIFIC GENES. EPIGENETIC CHANGES WERE ACCOMPANIED BY INCREASED EXPRESSION OF CARDIAC-SPECIFIC MARKERS. TRANSPLANTATION OF CHF RATS WITH EITHER CONTROL OR MOCE/C-KIT+ CELLS RESULTED IN AN IMPROVEMENT IN CARDIAC FUNCTION, RETARDATION OF CHF REMODELING MADE EVIDENT BY INCREASED VASCULARIZATION AND SCAR SIZE, AND CARDIOMYOCYTE HYPERTROPHY REDUCTION. COMPARED WITH CHF INFUSED WITH CONTROL CELLS, INFUSION OF MOCE/C-KIT+ CELLS RESULTED IN A FURTHER REDUCTION IN LEFT VENTRICLE END-DIASTOLIC PRESSURE AND TOTAL COLLAGEN AND AN INCREASE IN INTERLEUKIN-6 EXPRESSION. THE LOW ENGRAFTMENT OF INFUSED CELLS SUGGESTS THAT PARACRINE EFFECTS MIGHT ACCOUNT FOR THE BENEFICIAL EFFECTS OF C-KIT+ CELLS IN CHF. IN CONCLUSION, SELECTIVE INHIBITION OF CLASS I HDACS INDUCED EXPRESSION OF CARDIAC MARKERS IN C-KIT+ CELLS AND PARTIALLY AUGMENTED THE EFFICACY OF THESE CELLS FOR CHF REPAIR. SIGNIFICANCE: THE STUDY HAS SHOWN THAT SELECTIVE CLASS 1 HISTONE DEACETYLASE INHIBITION IS SUFFICIENT TO REDIRECT C-KIT+ CELLS TOWARD A CARDIAC FATE. EPIGENETICALLY MODIFIED C-KIT+ CELLS IMPROVED CONTRACTILE FUNCTION AND RETARDED REMODELING OF THE CONGESTIVE HEART FAILURE HEART. THIS STUDY PROVIDES NEW INSIGHTS INTO THE EFFICACY OF CARDIAC C-KIT+ CELLS IN THE ISCHEMIC HEART FAILURE MODEL. 2015 2 3332 40 HISTONE DEACETYLASE INHIBITOR-INDUCED EMERGENCE OF SYNAPTIC DELTA-OPIOID RECEPTORS AND BEHAVIORAL ANTINOCICEPTION IN PERSISTENT NEUROPATHIC PAIN. THE EFFICACY OF OPIOIDS IN PATIENTS WITH CHRONIC NEUROPATHIC PAIN REMAINS CONTROVERSIAL. ALTHOUGH ACTIVATION OF DELTA-OPIOID RECEPTORS (DORS) IN THE BRAINSTEM REDUCES INFLAMMATION-INDUCED PERSISTENT HYPERALGESIA, IT IS NOT EFFECTIVE UNDER PERSISTENT NEUROPATHIC PAIN CONDITIONS AND THESE CLINICAL PROBLEMS REMAIN LARGELY UNKNOWN. IN THIS STUDY, BY USING A CHRONIC CONSTRICTION INJURY (CCI) OF THE SCIATIC NERVE IN RATS, WE FOUND THAT IN THE BRAINSTEM NUCLEUS RAPHE MAGNUS (NRM), DORS EMERGED ON THE SURFACE MEMBRANE OF CENTRAL SYNAPTIC TERMINALS ON DAY 3 AFTER CCI SURGERY AND DISAPPEARED ON DAY 14. HISTONE DEACETYLASE (HDAC) INHIBITORS MICROINJECTED INTO THE NRM IN VIVO INCREASED THE LEVEL OF SYNAPTOSOMAL DOR PROTEIN AND NRM INFUSION OF DOR AGONISTS PRODUCING AN ANTINOCICEPTIVE EFFECT IN A NERVE GROWTH FACTOR (NGF) SIGNALING-DEPENDENT MANNER. IN VITRO, IN CCI RAT SLICES INCUBATED WITH HDAC INHIBITORS, DOR AGONISTS SIGNIFICANTLY INHIBITED EPSCS. THIS EFFECT WAS BLOCKED BY TYROSINE RECEPTOR KINASE A ANTAGONISTS. CHROMATIN IMMUNOPRECIPITATION ANALYSIS REVEALED THAT NRM INFUSION OF HDAC INHIBITORS IN CCI RATS INCREASED THE LEVEL OF HISTONE H4 ACETYLATION AT NGF GENE PROMOTER REGIONS. NGF WAS INFUSED INTO THE NRM OR INCUBATED CCI RAT SLICES DROVE DORS TO THE SURFACE MEMBRANE OF SYNAPTIC TERMINALS. TAKEN TOGETHER, EPIGENETIC UPREGULATION OF NGF ACTIVITY BY HDAC INHIBITORS IN THE NRM PROMOTES THE TRAFFICKING OF DORS TO PAIN-MODULATING NEURONAL SYNAPSES UNDER NEUROPATHIC PAIN CONDITIONS, LEADING TO DELTA-OPIOID ANALGESIA. THESE FINDINGS INDICATE THAT THERAPEUTIC USE OF DOR AGONISTS COMBINED WITH HDAC INHIBITORS MIGHT BE EFFECTIVE IN CHRONIC NEUROPATHIC PAIN MANAGEMENTS. 2016 3 5712 39 SIRT1 MEDIATES DEPRESSION-LIKE BEHAVIORS IN THE NUCLEUS ACCUMBENS. DEPRESSION IS A RECURRING AND LIFE-THREATENING ILLNESS THAT AFFECTS UP TO 120 MILLION PEOPLE WORLDWIDE. IN THE PRESENT STUDY, WE SHOW THAT CHRONIC SOCIAL DEFEAT STRESS, AN ETHOLOGICALLY VALIDATED MODEL OF DEPRESSION IN MICE, INCREASES SIRT1 LEVELS IN THE NUCLEUS ACCUMBENS (NAC), A KEY BRAIN REWARD REGION. INCREASES IN SIRT1, A WELL CHARACTERIZED CLASS III HISTONE DEACETYLASE, AFTER CHRONIC SOCIAL DEFEAT SUGGEST A ROLE FOR THIS ENZYME IN MEDIATING DEPRESSION-LIKE BEHAVIORS. WHEN RESVERATROL, A PHARMACOLOGICAL ACTIVATOR OF SIRT1, WAS DIRECTLY INFUSED BILATERALLY INTO THE NAC, WE OBSERVED AN INCREASE IN DEPRESSION- AND ANXIETY-LIKE BEHAVIORS. CONVERSELY, INTRA-NAC INFUSIONS OF EX-527, A SIRT1 ANTAGONIST, REDUCED THESE BEHAVIORS; EX-527 ALSO REDUCED ACUTE STRESS RESPONSES IN STRESS-NAIVE MICE. NEXT, WE INCREASED SIRT1 LEVELS DIRECTLY IN NAC BY USE OF VIRAL-MEDIATED GENE TRANSFER AND OBSERVED AN INCREASE IN DEPRESSIVE- AND ANXIETY-LIKE BEHAVIORS WHEN MICE WERE ASSESSED IN THE OPEN-FIELD, ELEVATED-PLUS-MAZE, AND FORCED SWIM TESTS. USING A CRE-INDUCIBLE VIRAL VECTOR SYSTEM TO OVEREXPRESS SIRT1 SELECTIVELY IN DOPAMINE D1 OR D2 SUBPOPULATIONS OF MEDIUM SPINY NEURONS (MSNS) IN THE NAC, WE FOUND THAT SIRT1 PROMOTES DEPRESSIVE-LIKE BEHAVIORS ONLY WHEN OVEREXPRESSED IN D1 MSNS, WITH NO EFFECT SEEN IN D2 MSNS. CONVERSELY, SELECTIVE ABLATION OF SIRT1 IN THE NAC USING VIRAL-CRE IN FLOXED SIRT1 MICE RESULTED IN DECREASED DEPRESSION- AND ANXIETY-LIKE BEHAVIORS. TOGETHER, THESE RESULTS DEMONSTRATE THAT SIRT1 PLAYS AN ESSENTIAL ROLE IN THE NAC IN REGULATING MOOD-RELATED BEHAVIORAL ABNORMALITIES AND IDENTIFIES A NOVEL SIGNALING PATHWAY FOR THE DEVELOPMENT OF INNOVATIVE ANTIDEPRESSANTS TO TREAT MAJOR DEPRESSIVE DISORDERS. SIGNIFICANCE STATEMENT: IN THIS STUDY, WE DEMONSTRATE A PIVOTAL ROLE FOR SIRT1 IN ANXIETY- AND DEPRESSION-LIKE BEHAVIORS IN THE NUCLEUS ACCUMBENS (NAC), A KEY BRAIN REWARD REGION. WE SHOW THAT STRESS STABLY INDUCES SIRT1 EXPRESSION IN THIS BRAIN REGION AND THAT ALTERING SIRT1 ACTIVITY USING A PHARMACOLOGICAL OR GENETIC APPROACH REGULATES ANXIETY- AND DEPRESSION-LIKE BEHAVIORS. THESE RESULTS SUGGEST THAT SIRT1 PLAYS AN ESSENTIAL ROLE IN REGULATING MOOD-RELATED BEHAVIORS AND INTRODUCES A NOVEL SIGNALING PATHWAY FOR THE DEVELOPMENT OF INNOVATIVE ANTIDEPRESSANTS TO TREAT DEPRESSION AND OTHER STRESS-RELATED DISORDERS. A RECENT GROUNDBREAKING PUBLICATION BY THE CONVERGE CONSORTIUM (2015) IDENTIFIED A REPRODUCIBLE ASSOCIATION OF THE SIRT1 LOCUS WITH MAJOR DEPRESSION IN HUMANS. THEREFORE, OUR RESULTS ARE TIMELY AND HAVE SIGNIFICANT TRANSLATIONAL RELEVANCE. 2016 4 5480 35 RESVERATROL REVERSES MORPHINE-INDUCED NEUROINFLAMMATION IN MORPHINE-TOLERANT RATS BY REVERSAL HDAC1 EXPRESSION. BACKGROUND/PURPOSE: WE PREVIOUSLY SHOWED THAT SUBSEQUENT INTRATHECAL (I.T.) INJECTION OF RESVERATROL (30 MUG) SIGNIFICANTLY REVERSES MORPHINE-EVOKED NEUROINFLAMMATION IN MORPHINE-TOLERANT RATS. THE PRESENT STUDY EXAMINED THE UNDERLYING MECHANISM. METHODS: MALE WISTAR RATS WERE IMPLANTED WITH TWO I.T. CATHETERS, ONE OF WHICH WAS CONNECTED TO A MINIOSMOTIC PUMP AND USED FOR MORPHINE (15 MUG/H) OR SALINE INFUSION FOR 120 HOURS. TO EXAMINE THE EFFECTS ON SPINAL CORD EXPRESSION OF HISTONE DEACETYLASE 1 (HDAC1), THE INFLAMMATORY CYTOKINE TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA), AND TNF RECEPTOR (TNFR) 1 AND TNFR2 DURING TOLERANCE INDUCTION, A TAIL-FLICK TEST WAS PERFORMED PRIOR TO INFUSION AND AFTER 24 HOURS, 48 HOURS, 72 HOURS, 96 HOURS, AND 120 HOURS OF INFUSION. RESULTS: RESVERATROL TREATMENT PRIOR TO MORPHINE CHALLENGE RESTORED THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN MORPHINE-TOLERANT RATS AND REVERSED THE MORPHINE INFUSION-INDUCED INCREASE IN HDAC1, TNF-ALPHA, AND TNFR1 EXPRESSION. MOREOVER, CHRONIC MORPHINE INFUSION INCREASED TNFR1-SPECIFIC EXPRESSION IN NEURON IN MORPHINE-TOLERANT RAT SPINAL CORDS, AND THIS EFFECT WAS ALMOST COMPLETELY INHIBITED BY RESVERATROL TREATMENT PRIOR TO MORPHINE CHALLENGE. CONCLUSION: RESVERATROL RESTORES THE ANTINOCICEPTIVE EFFECT OF MORPHINE BY REVERSING MORPHINE INFUSION-INDUCED SPINAL CORD NEUROINFLAMMATION AND INCREASE IN TNFR1 EXPRESSION. THE REVERSAL OF THE MORPHINE-INDUCED INCREASE IN TNFR1 EXPRESSION BY RESVERATROL IS PARTIALLY DUE TO REVERSAL OF THE MORPHINE INFUSION-INDUCED INCREASE IN HDAC1 EXPRESSION. RESVERATROL PRETREATMENT CAN BE USED AS AN ADJUVANT IN CLINICAL PAIN MANAGEMENT FOR PATIENTS WHO NEED LONG-TERM MORPHINE TREATMENT OR WITH NEUROPATHIC PAIN. 2016 5 1800 28 EFFECT OF HISTONE DEACETYLASE INHIBITOR ON ETHANOL WITHDRAWAL-INDUCED HYPERALGESIA IN RATS. BACKGROUND: INCREASED PAIN SENSITIVITY IS OBSERVED FOLLOWING ALCOHOL WITHDRAWAL, AND ATTEMPTS TO ALLEVIATE THIS HYPERALGESIA CAN CONTRIBUTE TO THE CYCLE OF ADDICTION. THE AIM OF THIS STUDY WAS TO DETERMINE IF ALCOHOL WITHDRAWAL-INDUCED HYPERALGESIA WAS OBSERVED IN A CHRONIC ETHANOL EXPOSURE MODEL AND IF THIS PAIN WAS AFFECTED BY HISTONE DEACETYLASE INHIBITORS, THUS REVEALING AN EPIGENETIC MECHANISM. METHODS: ADULT MALE SPRAGUE DAWLEY RATS RECEIVED LIEBER-DECARLI LIQUID CONTROL OR ETHANOL (9% V/V) DIET FOR 15 DAYS. MECHANICAL SENSITIVITY WAS MEASURED WITH VON FREY HAIR STIMULATION OF THE HINDPAW DURING ETHANOL ADMINISTRATION AND 24- AND 72-HOUR WITHDRAWAL. RESULTS: ETHANOL WITHDRAWAL PRODUCED SEVERE AND SUSTAINED MECHANICAL HYPERALGESIA, AN EFFECT NOT OBSERVED IN THE CONTROL OR ETHANOL-MAINTAINED GROUPS. FURTHERMORE, THIS HYPERALGESIA WAS ATTENUATED BY THE HISTONE DEACETYLASE INHIBITOR, SUBEROYLANILIDE HYDROXAMIC ACID TREATMENT. CONCLUSIONS: HEIGHTENED PAIN SENSITIVITY WAS OBSERVED FOLLOWING WITHDRAWAL FROM CHRONIC ETHANOL EXPOSURE, AND HISTONE DEACETYLASE INHIBITORS COULD BE NOVEL TREATMENTS FOR THIS ALCOHOL WITHDRAWAL-INDUCED HYPERALGESIA. 2019 6 113 43 A SELECTIVE HDAC 1/2 INHIBITOR MODULATES CHROMATIN AND GENE EXPRESSION IN BRAIN AND ALTERS MOUSE BEHAVIOR IN TWO MOOD-RELATED TESTS. PSYCHIATRIC DISEASES, INCLUDING SCHIZOPHRENIA, BIPOLAR DISORDER AND MAJOR DEPRESSION, ARE PROJECTED TO LEAD GLOBAL DISEASE BURDEN WITHIN THE NEXT DECADE. PHARMACOTHERAPY, THE PRIMARY--ALBEIT OFTEN INEFFECTIVE--TREATMENT METHOD, HAS REMAINED LARGELY UNCHANGED OVER THE PAST 50 YEARS, HIGHLIGHTING THE NEED FOR NOVEL TARGET DISCOVERY AND IMPROVED MECHANISM-BASED TREATMENTS. HERE, WE EXAMINED IN WILD TYPE MICE THE IMPACT OF CHRONIC, SYSTEMIC TREATMENT WITH COMPOUND 60 (CPD-60), A SLOW-BINDING, BENZAMIDE-BASED INHIBITOR OF THE CLASS I HISTONE DEACETYLASE (HDAC) FAMILY MEMBERS, HDAC1 AND HDAC2, IN MOOD-RELATED BEHAVIORAL ASSAYS RESPONSIVE TO CLINICALLY EFFECTIVE DRUGS. CPD-60 TREATMENT FOR ONE WEEK WAS ASSOCIATED WITH ATTENUATED LOCOMOTOR ACTIVITY FOLLOWING ACUTE AMPHETAMINE CHALLENGE. FURTHER, TREATED MICE DEMONSTRATED DECREASED IMMOBILITY IN THE FORCED SWIM TEST. THESE CHANGES ARE CONSISTENT WITH ESTABLISHED EFFECTS OF CLINICAL MOOD STABILIZERS AND ANTIDEPRESSANTS, RESPECTIVELY. WHOLE-GENOME EXPRESSION PROFILING OF SPECIFIC BRAIN REGIONS (PREFRONTAL CORTEX, NUCLEUS ACCUMBENS, HIPPOCAMPUS) FROM MICE TREATED WITH CPD-60 IDENTIFIED GENE EXPRESSION CHANGES, INCLUDING A SMALL SUBSET OF TRANSCRIPTS THAT SIGNIFICANTLY OVERLAPPED THOSE PREVIOUSLY REPORTED IN LITHIUM-TREATED MICE. HDAC INHIBITION IN BRAIN WAS CONFIRMED BY INCREASED HISTONE ACETYLATION BOTH GLOBALLY AND, USING CHROMATIN IMMUNOPRECIPITATION, AT THE PROMOTER REGIONS OF UPREGULATED TRANSCRIPTS, A FINDING CONSISTENT WITH IN VIVO ENGAGEMENT OF HDAC TARGETS. IN CONTRAST, TREATMENT WITH SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), A NON-SELECTIVE FAST-BINDING, HYDROXAMIC ACID HDAC 1/2/3/6 INHIBITOR, WAS SUFFICIENT TO INCREASE HISTONE ACETYLATION IN BRAIN, BUT DID NOT ALTER MOOD-RELATED BEHAVIORS AND HAD DISSIMILAR TRANSCRIPTIONAL REGULATORY EFFECTS COMPARED TO CPD-60. THESE RESULTS PROVIDE EVIDENCE THAT SELECTIVE INHIBITION OF HDAC1 AND HDAC2 IN BRAIN MAY PROVIDE AN EPIGENETIC-BASED TARGET FOR DEVELOPING IMPROVED TREATMENTS FOR MOOD DISORDERS AND OTHER BRAIN DISORDERS WITH ALTERED CHROMATIN-MEDIATED NEUROPLASTICITY. 2013 7 3331 40 HISTONE DEACETYLASE INHIBITOR SUBERANILOHYDROXAMIC ACID TREATMENT REVERSES HYPOSENSITIVITY TO GAMMA-AMINOBUTYRIC ACID IN THE VENTRAL TEGMENTAL AREA DURING ETHANOL WITHDRAWAL. BACKGROUND: THE VENTRAL TEGMENTAL AREA (VTA) IS IMPORTANT FOR ALCOHOL-RELATED REWARD AND REINFORCEMENT. MOUSE VTA NEURONS ARE HYPOSENSITIVE TO GAMMA-AMINOBUTYRIC ACID (GABA) DURING ETHANOL (ETOH) WITHDRAWAL, AND GABA RESPONSIVENESS IS NORMALIZED BY IN VITRO TREATMENT WITH HISTONE DEACETYLASE INHIBITORS (HDACI). THE PRESENT STUDY EXAMINED THE EFFECT OF A SYSTEMICALLY ADMINISTERED HDACI, SUBERANILOHYDROXAMIC ACID (SAHA) ON GABA SENSITIVITY, AND RELATED MOLECULAR CHANGES IN VTA NEURONS DURING WITHDRAWAL AFTER CHRONIC ETOH INTAKE IN RATS. METHODS: SPRAGUE DAWLEY MALE ADULT RATS WERE FED WITH LIEBER-DECARLI DIET (9% ETOH OR CONTROL DIET) FOR 16 DAYS. EXPERIMENTAL GROUPS INCLUDED CONTROL DIET-FED AND ETOH DIET-FED (0- OR 24-HOUR WITHDRAWAL) RATS TREATED WITH EITHER SAHA OR VEHICLE INJECTION. SINGLE-UNIT RECORDINGS WERE USED TO MEASURE THE RESPONSE OF VTA NEURONS TO GABA. IMMUNOHISTOCHEMISTRY WAS PERFORMED TO EXAMINE LEVELS OF HDAC2, ACETYLATED HISTONE H3 LYSINE 9 (ACH3K9), AND GABA(A) RECEPTOR ALPHA1 AND ALPHA5 SUBUNITS IN THE VTA; QUANTITATIVE POLYMERASE CHAIN REACTION WAS PERFORMED TO EXAMINE THE MRNA LEVELS OF HDAC2 AND GABA(A) RECEPTOR SUBUNITS. RESULTS: VTA NEURONS FROM THE WITHDRAWAL GROUP EXHIBITED GABA HYPOSENSITIVITY. IN VIVO SAHA TREATMENT 2 HOURS BEFORE SACRIFICE NORMALIZED THE SENSITIVITY OF VTA NEURONS TO GABA. ETOH WITHDRAWAL WAS ASSOCIATED WITH INCREASED HDAC2 AND DECREASED ACH3K9 PROTEIN LEVELS; SAHA TREATMENT NORMALIZED ACH3K9 LEVELS. INTERESTINGLY, NO SIGNIFICANT CHANGE WAS OBSERVED IN THE MRNA LEVELS OF HDAC2. THE MRNA LEVELS, BUT NOT PROTEIN LEVELS, OF GABA(A) RECEPTOR ALPHA1 AND ALPHA5 SUBUNITS WERE INCREASED DURING WITHDRAWAL. CONCLUSIONS: WITHDRAWAL FROM CHRONIC ETOH EXPOSURE RESULTS IN A DECREASE IN GABA-MEDIATED INHIBITION, AND THIS GABA HYPOSENSITIVITY IS NORMALIZED BY IN VIVO SAHA TREATMENT. DISRUPTION OF SIGNALING IN THE VTA PRODUCED BY ALTERATION OF GABA NEUROTRANSMISSION COULD BE 1 NEUROADAPTIVE PHYSIOLOGICAL PROCESS LEADING TO CRAVING AND RELAPSE. THESE RESULTS SUGGEST THAT HDACI PHARMACOTHERAPY WITH AGENTS LIKE SAHA MIGHT BE AN EFFECTIVE TREATMENT FOR ALCOHOLISM. 2018 8 4148 32 MECHANISTIC BASIS OF EX VIVO UMBILICAL CORD BLOOD STEM PROGENITOR CELL EXPANSION. UMBILICAL CORD BLOOD (CB) TRANSPLANTATION HAS BEEN USED SUCCESSFULLY IN HUMANS FOR THREE DECADES DUE TO ITS RAPID AVAILABILITY FOR PATIENTS LACKING A SUITABLE ALLOGENEIC DONOR, LESS STRINGENT HLA MATCHING REQUIREMENTS, AND LOW RATES OF RELAPSE AND CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD). HOWEVER, CB TRANSPLANTATION IS ASSOCIATED WITH COMPLICATIONS, SUCH AS DELAYED HEMATOPOIETIC ENGRAFTMENT, GRAFT FAILURE, WHICH INCREASES INFECTION AND BLEEDING AND CAUSES LONGER HOSPITAL STAYS, AND TRANSPLANT-RELATED MORTALITY. THE MAJORITY OF THESE BIOLOGICAL LIMITATIONS ARE DUE TO THE UNFORESEEABLE FUNCTIONAL POTENCY OF MULTIPOTENT HEMATOPOIETIC STEM CELLS (HSCS), WHICH REDUCE THE PREDICTABILITY OF SUCCESSFUL TRANSPLANTATION; HOWEVER, SEVERAL STRATEGIES HAVE BEEN DEVELOPED TO INCREASE THE NUMBER OF HEMATOPOIETIC STEM PROGENITOR CELLS (HSPCS) INFUSED DURING CB TRANSPLANTATION. THIS REVIEW PRIMARILY ADDRESSES THE METHODS THAT PROMOTE EX VIVO CB EXPANSION WITHIN THE CONTEXT OF SYMMETRICAL AND ASYMMETRICAL HSC DIVISION AND THOSE THAT RELY ON EPIGENETIC MECHANISMS, ALONG WITH THE REPORTEDLY MOST SUCCESSFUL CYTOKINE COMBINATIONS. WE ALSO REVIEW RECENT CLINICAL RESEARCH ON SMALL MOLECULES (STEMREGENIN-1, UM171, AND NICOTINAMIDE) IN EX VIVO EXPANDED CB AND DISCUSS YET UNVALIDATED PRECLINICAL STRATEGIES. EXPANDING AND TRANSPLANTING CB GRAFT ENRICHED IN HSPCS IN A SINGLE CB UNIT IS A PARTICULARLY EXCITING PROSPECT WITH THE POTENTIAL TO IMPROVE THE USE AND AVAILABILITY OF CB GRAFTS. GREATER KNOWLEDGE OF OPTIMAL EX VIVO EXPANSION STRATEGIES, CELL LONGEVITY, AND GRAFT POTENCY WILL EXPAND THE SCOPE OF CELLULAR THERAPIES. ALSO THE DEVELOPMENT OF ADEQUATE EX VIVO HSPC EXPANSION STRATEGIES COULD BRING EXPANDED CORD BLOOD GRAFTS TO THE FOREFRONT OF TRANSPLANT THERAPY AND REGENERATIVE MEDICINE. 2020 9 5781 37 SPINAL SIRT1 ACTIVATION ATTENUATES NEUROPATHIC PAIN IN MICE. ABNORMAL HISTONE ACETYLATION OCCURS DURING NEUROPATHIC PAIN THROUGH AN EPIGENETIC MECHANISM. SILENT INFORMATION REGULATOR 1 (SIR2 OR SIRT1), A NAD-DEPENDENT DEACETYLASE, PLAYS COMPLEX SYSTEMIC ROLES IN A VARIETY OF PROCESSES THROUGH DEACETYLATING ACETYLATED HISTONE AND OTHER SPECIFIC SUBSTRATES. BUT THE ROLE OF SIRT1 IN NEUROPATHIC PAIN IS NOT WELL ESTABLISHED YET. THE PRESENT STUDY WAS INTENDED TO DETECT SIRT1 CONTENT AND ACTIVITY, NICOTINAMIDE (NAM) AND NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) IN THE SPINAL CORD USING IMMUNOBLOTTING OR MASS SPECTROSCOPY OVER TIME IN MICE FOLLOWING CHRONIC CONSTRICTION INJURY (CCI) OR SHAM SURGERY. IN ADDITION, THE EFFECT OF INTRATHECAL INJECTION OF NAD OR RESVERATROL ON THERMAL HYPERALGESIA AND MECHANICAL ALLODYNIA WAS EVALUATED IN CCI MICE. FINALLY, WE INVESTIGATED WHETHER SIRT1 INHIBITOR EX-527 COULD REVERSE THE ANTI-NOCICEPTIVE EFFECT OF NAD OR RESVERATROL. IT WAS FOUND THAT SPINAL SIRT1 EXPRESSION, DEACETYLASE ACTIVITY AND NAD/NAM DECREASED SIGNIFICANTLY 1, 3, 7, 14 AND 21 DAYS AFTER CCI SURGERY AS COMPARED WITH SHAM GROUP. IN ADDITION, DAILY INTRATHECAL INJECTION OF 5 MICROL 800 MM NAD 1 H BEFORE AND 1 DAY AFTER CCI SURGERY OR SINGLE INTRATHECAL INJECTION OF 5 MICROL 90 MM RESVERATROL 1 H BEFORE CCI SURGERY PRODUCED A TRANSIENT INHIBITORY EFFECT ON THERMAL HYPERALGESIA AND MECHANICAL ALLODYNIA IN CCI MICE. FINALLY, AN INTRATHECAL INJECTION OF 5 MICROL 1.2 MM EX-527 1 H BEFORE NAD OR RESVERATROL ADMINISTRATION REVERSED THE ANTI-NOCICEPTIVE EFFECT OF NAD OR RESVERATROL. THESE DATA INDICATE THAT THE REDUCTION IN SIRT1 DEACETYLASE ACTIVITY MAY BE A FACTOR CONTRIBUTING TO THE DEVELOPMENT OF NEUROPATHIC PAIN IN CCI MICE. OUR FINDINGS SUGGEST THAT THE ENHANCEMENT OF SPINAL NAD/NAM AND/OR SIRT1 ACTIVITY MAY BE A POTENTIALLY PROMISING STRATEGY FOR THE PREVENTION OR TREATMENT OF NEUROPATHIC PAIN. 2014 10 2750 35 EXPRESSION LEVELS OF THE TYROSINE HYDROXYLASE GENE AND HISTONE MODIFICATIONS AROUND ITS PROMOTER IN THE LOCUS COERULEUS AND VENTRAL TEGMENTAL AREA OF RATS DURING FORCED ABSTINENCE FROM MORPHINE. BACKGROUND: EPIGENETIC MECHANISMS SUCH AS HISTONE MODIFICATIONS MAY BE INVOLVED IN THE STRUCTURAL AND BEHAVIORAL CHANGES ASSOCIATED WITH ADDICTION. WE STUDIED WHETHER MORPHINE-INDUCED CHANGES IN MRNA LEVELS OF THE CATECHOLAMINE BIOSYNTHESIS ENZYME, TYROSINE HYDROXYLASE (TH), ARE ASSOCIATED WITH HISTONE MODIFICATIONS AROUND THE PROMOTER OF THIS GENE IN THE LOCUS COERULEUS (LC) AND VENTRAL TEGMENTAL AREA (VTA) OF RATS. METHODS: DEPENDENCE WAS INDUCED IN RATS BY INTRAPERITONEAL INJECTIONS OF MORPHINE FOR 11 DAYS. THE ANIMALS WERE KILLED 2 H (CHRONIC MORPHINE), 24 H AND 7 DAYS (SPONTANEOUS WITHDRAWAL) AFTER THE LAST INJECTION OF MORPHINE. RESULTS: ANALYSIS OF OUR REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION PCR RESULTS BY 1-WAY ANOVA SHOWED SIGNIFICANT UPREGULATION (5.13 +/- 0.39 FOLDS) OF LC LEVELS OF THE TH TRANSCRIPT 24 H AFTER THE LAST INJECTION OF MORPHINE TO RATS, WHEN COMPARED WITH 2 H AND 7 DAYS TIME POINTS. CHRONIC MORPHINE AND MORPHINE ABSTINENCE FAILED TO CAUSE ANY SIGNIFICANT CHANGES IN THE LEVELS OF TH MRNA IN THE VTA AFTER CESSATION OF MORPHINE. CONSISTENTLY, CHROMATIN IMMUNOPRECIPITATION REAL-TIME QUANTITATIVE PCR ASSAYS REVEALED THAT 24 H AFTER THE LAST INJECTION OF MORPHINE, LEVELS OF H3 ACETYLATION WERE SIGNIFICANTLY INCREASED (4.12 +/- 0.38 FOLDS) AT THE PROMOTER OF THE TH GENE IN THE LC BUT NOT IN THE VTA. OUR DATA ALSO SHOWED THAT HISTONE H3 TRIMETHYLATION FAILED TO CHANGE AROUND THE TH GENE PROMOTER EITHER IN THE VTA OR IN THE LC AFTER MORPHINE ABSTINENCE. CONCLUSIONS: RESULTS OF THE PRESENT STUDY, FOR THE FIRST TIME, DEMONSTRATE THE INVOLVEMENT OF HISTONE H3 ACETYLATION IN THE REGULATION OF TH GENE EXPRESSION IN THE LC OF RATS DURING FORCED ABSTINENCE FROM MORPHINE. 2018 11 2120 39 EPIGENETIC HISTONE MODIFICATIONS IN A CLINICALLY RELEVANT RAT MODEL OF CHRONIC ETHANOL-BINGE-MEDIATED LIVER INJURY. PURPOSE: ETHANOL BINGE AUGMENTS LIVER INJURY AFTER CHRONIC ETHANOL CONSUMPTION IN HUMANS, BUT THE MECHANISM BEHIND THE ENHANCED LIVER INJURY BY ETHANOL BINGE IS NOT KNOWN. IN THIS STUDY WE USED A CLINICALLY RELEVANT RAT MODEL IN WHICH LIVER INJURY IS AMPLIFIED BY BINGE AFTER CHRONIC ETHANOL TREATMENT AND INVESTIGATED THE IMPORTANCE OF HISTONE MODIFICATIONS. METHODS: EIGHT-WEEK-OLD SPRAGUE-DAWLEY RATS WERE FED ETHANOL IN A LIQUID DIET FOR 4 WEEKS. CONTROL RATS WERE FED AN ISOCALORIC LIQUID DIET. THIS WAS FOLLOWED BY THREE BINGE ADMINISTRATIONS OF ETHANOL (INTRAGASTRIC 5 G/KG BODY WEIGHT, 12 H APART). IN THE CONTROL, ETHANOL WAS REPLACED BY WATER. FOUR HOURS AFTER THE LAST BINGE ADMINISTRATION, LIVER SAMPLES WERE ANALYZED FOR HISTONE MODIFICATIONS AND PARAMETERS OF LIVER INJURY. RESULTS: CHRONIC ETHANOL ADMINISTRATION ALONE CAUSED AN INCREASE IN HISTONE H3 SER10 AND SER28 (H3S10 OR S28) PHOSPHORYLATION, AND BINGE ETHANOL REDUCED THEIR LEVELS. LEVELS OF DUALLY MODIFIED PHOSPHOACETYLATED HISTONE H3 (H3ACK9/PS10) INCREASED AFTER ACUTE BINGE ETHANOL AND REMAINED SAME AFTER CHRONIC ETHANOL BINGE. IN CONTRAST, HISTONE H3 LYSINE-9 ACETYLATION (H3ACK9) WAS NOT INCREASED AFTER CHRONIC ETHANOL BUT INCREASED SIGNIFICANTLY AFTER ACUTE BINGE AND CHRONIC ETHANOL BINGE. INCREASE IN HISTONE ACETYLATION WAS ACCOMPANIED BY INCREASED PHOSPHO-ERK1/2 IN THE NUCLEAR EXTRACTS. INCREASED ACETYLATION AFTER CHRONIC ETHANOL BINGE WAS ALSO ACCOMPANIED BY INCREASED PROTEIN LEVELS OF GCN5 HISTONE ACETYL TRANSFERASE AND A MODEST INCREASE IN HDAC3 IN THE NUCLEUS. HISTONE LYSINE-9 DIMETHYLATION WAS SIGNIFICANTLY INCREASED AFTER CHRONIC ETHANOL BINGE. CHRONIC ETHANOL BINGE ALSO RESULTED IN A DECREASE IN THE SAM:SAH RATIO WITH A RELATIVE DECREASE OF SAM LEVELS AND A CORRESPONDING INCREASE IN SAH LEVELS. CONCLUSIONS: ETHANOL BINGE AFTER CHRONIC ETHANOL ALTERED THE PROFILE OF SITE-SPECIFIC HISTONE MODIFICATIONS AND MAY UNDERLIE THE MECHANISM OF AUGMENTED LIVER INJURY BY CHRONIC-ETHANOL-BINGE-TREATED RATS. 2014 12 1003 37 CHRONIC TREATMENT WITH FLUOXETINE INDUCES SEX-DEPENDENT ANALGESIC EFFECTS AND MODULATES HDAC2 AND MGLU2 EXPRESSION IN FEMALE MICE. GENDER AND SEX DIFFERENCES IN PAIN RECOGNITION AND DRUG RESPONSES HAVE BEEN REPORTED IN CLINICAL TRIALS AND EXPERIMENTAL MODELS OF PAIN. AMONG ANTIDEPRESSANTS, CONTRADICTORY RESULTS HAVE BEEN OBSERVED IN PATIENTS TREATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS). THIS STUDY EVALUATED SEX DIFFERENCES IN RESPONSE TO THE SSRI FLUOXETINE AFTER CHRONIC ADMINISTRATION IN THE MOUSE FORMALIN TEST. ADULT MALE AND FEMALE CD1 MICE WERE INTRAPERITONEALLY INJECTED WITH FLUOXETINE (10 MG/KG) FOR 21 DAYS AND SUBJECTED TO PAIN ASSESSMENT. FLUOXETINE TREATMENT REDUCED THE SECOND PHASE OF THE FORMALIN TEST ONLY IN FEMALE MICE WITHOUT PRODUCING BEHAVIORAL CHANGES IN MALES. WE ALSO OBSERVED THAT FLUOXETINE WAS ABLE TO SPECIFICALLY INCREASE THE EXPRESSION OF METABOTROPIC GLUTAMATE RECEPTOR TYPE-2 (MGLU2) IN FEMALES. ALSO A REDUCED EXPRESSION OF THE EPIGENETIC MODIFYING ENZYME, HISTONE DEACETYLASE 2 (HDAC2), IN DORSAL ROOT GANGLIA (DRG) AND DORSAL HORN (DH) TOGETHER WITH AN INCREASE HISTONE 3 ACETYLATION (H3) LEVEL WAS OBSERVED IN FEMALES BUT NOT IN MALES. WITH THIS STUDY WE PROVIDE EVIDENCE THAT FLUOXETINE INDUCES SEX SPECIFIC CHANGES IN HDAC2 AND MGLU2 EXPRESSION IN THE DH OF THE SPINAL CORD AND IN DRGS AND SUGGESTS A MOLECULAR EXPLANATION FOR THE ANALGESIC EFFECTS IN FEMALE MICE. 2017 13 687 38 BRAINSTEM BRAIN-DERIVED NEUROTROPHIC FACTOR SIGNALING IS REQUIRED FOR HISTONE DEACETYLASE INHIBITOR-INDUCED PAIN RELIEF. OUR PREVIOUS STUDY DEMONSTRATED THAT PERSISTENT PAIN CAN EPIGENETICALLY SUPPRESS THE TRANSCRIPTION OF GAD2 [ENCODING GLUTAMIC ACID DECARBOXYLASE 65 (GAD65)] AND CONSEQUENTLY IMPAIR THE INHIBITORY FUNCTION OF GABAERGIC SYNAPSES IN CENTRAL PAIN-MODULATING NEURONS. THIS CONTRIBUTES TO THE DEVELOPMENT OF PERSISTENT PAIN SENSITIZATION. HISTONE DEACETYLASE (HDAC) INHIBITORS INCREASED GAD65 ACTIVITY CONSIDERABLY, RESTORED GABA SYNAPTIC FUNCTION, AND RENDERED SENSITIZED PAIN BEHAVIOR LESS PRONOUNCED. HOWEVER, THE MOLECULAR MECHANISMS BY WHICH HDAC REGULATES GABAERGIC TRANSMISSION THROUGH GAD65 UNDER PAIN CONDITIONS ARE UNKNOWN. THIS WORK SHOWED THAT HDAC INHIBITOR-INDUCED INCREASES IN COLOCALIZATION OF GAD65 AND SYNAPTIC PROTEIN SYNAPSIN I ON THE PRESYNAPTIC AXON TERMINALS OF THE NUCLEUS RAPHE MAGNUS (NRM) WERE BLOCKED BY A TRKB RECEPTOR ANTAGONIST K252A [(9S,10R,12R)-2,3,9,10,11,12-HEXAHYDRO-10-HYDROXY-9-METHYL-1-OXO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-10-CARBOXYLIC ACID METHYL ESTER], INDICATING THAT BDNF-TRKB SIGNALING MAY BE REQUIRED IN GAD65 MODULATION OF GABA SYNAPTIC FUNCTION. AT THE BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) PROMOTER, HDAC INHIBITORS INDUCED SIGNIFICANT INCREASES IN H3 HYPERACETYLATION, CONSISTENT WITH THE INCREASE IN BDNF MRNA AND TOTAL PROTEINS. ALTHOUGH EXOGENOUS BDNF FACILITATED GABA MINIATURE INHIBITORY POSTSYNAPTIC CURRENTS AND GAD65 ACCUMULATION IN NRM NEURONAL SYNAPSES IN NORMAL RATS, IT FAILED TO DO SO IN ANIMALS SUBJECTED TO PERSISTENT INFLAMMATION. IN ADDITION, BLOCKADE OF THE TRKB RECEPTOR WITH K252A HAS NO EFFECT ON MINIATURE INHIBITORY POSTSYNAPTIC CURRENTS AND SYNAPTIC GAD65 ACCUMULATION UNDER NORMAL CONDITIONS. IN ADDITION, THE ANALGESIC EFFECTS OF HDAC INHIBITORS ON BEHAVIOR WERE BLOCKED BY NRM INFUSION OF K252A. THESE FINDINGS SUGGEST THAT BDNF-TRKB SIGNALING IS REQUIRED FOR DRUGS THAT REVERSE THE EPIGENETIC EFFECTS OF CHRONIC PAIN AT THE GENE LEVEL, SUCH AS HDAC INHIBITORS. 2015 14 6175 37 THE HISTONE DEACETYLASE INHIBITOR SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) ALLEVIATES DEPRESSION-LIKE BEHAVIOR AND NORMALIZES EPIGENETIC CHANGES IN THE HIPPOCAMPUS DURING ETHANOL WITHDRAWAL. WITHDRAWAL FROM CHRONIC ALCOHOL DRINKING CAN CAUSE DEPRESSION, LEADING TO AN INABILITY TO FUNCTION IN DAILY LIFE AND AN INCREASED RISK FOR RELAPSE TO HARMFUL DRINKING. UNDERSTANDING THE CAUSES OF ALCOHOL WITHDRAWAL-RELATED DEPRESSION MAY LEAD TO NEW THERAPEUTIC TARGETS FOR TREATMENT. EPIGENETIC FACTORS HAVE RECENTLY EMERGED AS IMPORTANT CONTRIBUTORS TO BOTH DEPRESSION AND ALCOHOL USE DISORDER (AUD). SPECIFICALLY, ACETYLATION OF THE N-TERMINAL TAILS OF HISTONE PROTEINS THAT PACKAGE DNA INTO NUCLEOSOMES IS ALTERED IN STRESS-INDUCED MODELS OF DEPRESSION AND DURING ALCOHOL WITHDRAWAL. THE GOAL OF THIS STUDY WAS TO EXAMINE DEPRESSION-LIKE BEHAVIOR DURING ALCOHOL WITHDRAWAL AND ASSOCIATED CHANGES IN HISTONE ACETYLATION AND EXPRESSION OF HISTONE DEACETYLASE 2 (HDAC2) IN THE HIPPOCAMPUS, A BRAIN REGION CRITICAL FOR MOOD REGULATION AND DEPRESSION. MALE SPRAGUE-DAWLEY RATS WERE TREATED WITH THE LIEBER-DECARLI ETHANOL LIQUID DIET FOR 15 DAYS AND THEN UNDERWENT WITHDRAWAL. RATS WERE TREATED WITH THE HDAC INHIBITOR, SUBEROYLANILIDE HYDROXAMIC ACID (SAHA), DURING WITHDRAWAL AND WERE TESTED FOR DEPRESSION-LIKE BEHAVIOR. IN A SEPARATE GROUP OF RATS, THE HIPPOCAMPUS WAS ANALYZED FOR MRNA AND PROTEIN EXPRESSION OF HDAC2 AND LEVELS OF HISTONE H3 LYSINE 9 ACETYLATION (H3K9AC) DURING CHRONIC ETHANOL EXPOSURE AND WITHDRAWAL. RATS UNDERGOING ETHANOL WITHDRAWAL EXHIBITED DEPRESSION-LIKE BEHAVIOR AND HAD INCREASED HDAC2 AND DECREASED H3K9AC LEVELS IN SPECIFIC STRUCTURES OF THE HIPPOCAMPUS. TREATMENT WITH SAHA DURING WITHDRAWAL AMELIORATED DEPRESSION-LIKE BEHAVIOR AND NORMALIZED CHANGES IN HIPPOCAMPAL HDAC2 AND H3K9AC LEVELS. THESE RESULTS DEMONSTRATE THAT ETHANOL WITHDRAWAL CAUSES AN ALTERED EPIGENETIC STATE IN THE HIPPOCAMPUS. TREATMENT WITH AN HDAC INHIBITOR CAN CORRECT THIS STATE AND ALLEVIATE DEPRESSION-LIKE SYMPTOMS DEVELOPED DURING WITHDRAWAL. TARGETING HISTONE ACETYLATION MAY BE A NOVEL STRATEGY TO REDUCE ETHANOL WITHDRAWAL-INDUCED DEPRESSION. 2019 15 2353 41 EPIGENETIC REGULATION OF OPIOID-INDUCED HYPERALGESIA, DEPENDENCE, AND TOLERANCE IN MICE. REPEATED ADMINISTRATION OF OPIOIDS SUCH AS MORPHINE INDUCES PERSISTENT BEHAVIORAL CHANGES INCLUDING OPIOID-INDUCED HYPERALGESIA (OIH), TOLERANCE, AND PHYSICAL DEPENDENCE. IN THE CURRENT WORK WE EXPLORED HOW THE BALANCE OF HISTONE ACETYLTRANSFERASE (HAT) VERSUS HISTONE DEACETYLASE (HDAC) MIGHT REGULATE THESE MORPHINE-INDUCED CHANGES. NOCICEPTIVE THRESHOLDS, ANALGESIA, AND PHYSICAL DEPENDENCE WERE ASSESSED DURING AND FOR A PERIOD OF SEVERAL WEEKS AFTER MORPHINE EXPOSURE. TO PROBE THE ROLES OF HISTONE ACETYLATION, THE HAT INHIBITOR CURCUMIN OR A SELECTIVE HDAC INHIBITOR SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) WAS ADMINISTERED DAILY TO GROUPS OF ANIMALS. HISTONE ACETYLATION IN SPINAL CORD WAS ASSESSED BY WESTERN BLOT AND IMMUNOHISTOCHEMISTRY. CONCURRENT ADMINISTRATION OF CURCUMIN WITH MORPHINE FOR 4 DAYS SIGNIFICANTLY REDUCED DEVELOPMENT OF OPIOID-INDUCED MECHANICAL ALLODYNIA, THERMAL HYPERALGESIA, TOLERANCE, AND PHYSICAL DEPENDENCE. CONVERSELY, THE HDAC INHIBITOR SAHA ENHANCED THESE RESPONSES. INTERESTINGLY, SAHA TREATMENT AFTER THE TERMINATION OF OPIOID ADMINISTRATION SUSTAINED THESE BEHAVIORAL CHANGES FOR AT LEAST 4 WEEKS. HISTONE H3 ACETYLATION IN THE DORSAL HORN OF THE SPINAL CORD WAS INCREASED AFTER CHRONIC MORPHINE TREATMENT, BUT H4 ACETYLATION WAS UNCHANGED. MOREOVER, WE OBSERVED A DECREASE IN HDAC ACTIVITY IN THE SPINAL CORDS OF MORPHINE-TREATED MICE WHILE OVERALL HAT ACTIVITY WAS UNCHANGED, SUGGESTING A SHIFT TOWARD A STATE OF ENHANCED HISTONE ACETYLATION. PERSPECTIVE: THE CURRENT STUDY INDICATES THAT EPIGENETIC MECHANISMS PLAY A CRUCIAL ROLE IN OPIOID-INDUCED LONG-LASTING NEUROPLASTICITY. THESE RESULTS PROVIDE NEW SIGHT INTO UNDERSTANDING THE MECHANISMS OF OPIOID-INDUCED NEUROPLASTICITY AND SUGGEST NEW STRATEGIES TO LIMIT OPIOID ABUSE POTENTIAL AND INCREASE THE VALUE OF THESE DRUGS AS ANALGESICS. 2013 16 6612 32 ULTRA-LOW-DOSE NALOXONE ENHANCES THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN PTX-TREATED RATS: REGULATION ON GLOBAL HISTONE METHYLATION. OBJECTIVE: EPIGENETIC REPROGRAMMING MAY HAVE A POSSIBLE ROLE IN NEUROPATHIC PAIN DEVELOPMENT; THE PRESENT STUDY EXAMINED THE GLOBAL PATTERNS OF LYSINE HISTONE MODIFICATION. IN THIS SERIAL STUDY WE ANALYZED THE LEVELS OF HISTONE 3 LYSINE 4 MONOMETHYLATION, HISTONE 3 LYSINE 4 DIMETHYLATION, AND HISTONE 3 LYSINE 9 TRIMETHYLATION IN PERTUSSIS TOXIN (PTX)-INDUCED THERMAL HYPERALGESIC RAT SPINAL CORDS. METHODS: MALE WISTAR RATS IMPLANTED WITH AN INTRATHECAL CATHETER RECEIVED A SINGLE INTRATHECAL PTX (1 MUG IN 5 MUL SALINE) INJECTION. FOUR DAYS LATER, THEY WERE RANDOMLY ASSIGNED TO RECEIVE EITHER A SINGLE INJECTION OF SALINE, OR ULTRA-LOW-DOSE NALOXONE (15 NG IN 5 MUL SALINE), FOLLOWED BY MORPHINE (10 MUG IN 5 MUL SALINE) INJECTION 30 MINUTES LATER. RESULTS: THE RESULTS SHOWED THAT PTX INJECTION INDUCED THERMAL HYPERALGESIA AND SIGNIFICANT INCREASE OF GLOBAL HISTONE METHYLATION IN THE SPINAL CORDS. INTRATHECAL MORPHINE ALONE DID NOT AFFECT THE THERMAL HYPERALGESIA AND GLOBAL HISTONE METHYLATION. IN CONTRAST, INTRATHECAL ADMINISTRATION OF ULTRA-LOW-DOSE NALOXONE PLUS MORPHINE SIGNIFICANTLY ATTENUATED THE PTX-INDUCED THERMAL HYPERALGESIA AND DOWN-REGULATED THE GLOBAL HISTONE METHYLATION. CONCLUSION: THE RESULTS SUGGEST THAT ULTRA-LOW-DOSE NALOXONE MIGHT BE CLINICAL VALUABLE FOR NEUROPATHIC PAIN MANAGEMENT VIA REGULATING GLOBAL HISTONE MODIFICATION. 2012 17 2364 48 EPIGENETIC REGULATION OF SPINAL CORD GENE EXPRESSION CONTROLS OPIOID-INDUCED HYPERALGESIA. BACKGROUND: THE LONG TERM USE OF OPIOIDS FOR THE TREATMENT OF PAIN LEADS TO A GROUP OF MALADAPTATIONS WHICH INCLUDES OPIOID-INDUCED HYPERALGESIA (OIH). OIH TYPICALLY RESOLVES WITHIN FEW DAYS AFTER CESSATION OF MORPHINE TREATMENT IN MICE BUT IS PROLONGED FOR WEEKS IF HISTONE DEACETYLASE (HDAC) ACTIVITY IS INHIBITED DURING OPIOID TREATMENT. THE PRESENT WORK SEEKS TO IDENTIFY GENE TARGETS SUPPORTING THE EPIGENETIC EFFECTS RESPONSIBLE FOR OIH PROLONGATION. RESULTS: MICE WERE TREATED WITH MORPHINE ACCORDING TO AN ASCENDING DOSE PROTOCOL. SOME MICE ALSO RECEIVED THE SELECTIVE HDAC INHIBITOR SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) ADDITIONALLY. CHRONIC MORPHINE TREATMENT WITH SIMULTANEOUS HDAC INHIBITION ENHANCED OIH, AND SEVERAL SPINAL CORD GENES WERE UP-REGULATED. THE EXPRESSION OF BDNF (BRAIN-DERIVED NEUROTROPHIC FACTOR) AND PDYN (PRODYNORPHIN) WERE MOST CLOSELY RELATED TO THE OBSERVED BEHAVIORAL CHANGES. CHIP (CHROMATIN IMMUOPRECIPATION) ASSAYS DEMONSTRATED THAT PROMOTER REGIONS OF PDYN AND BDNF WERE STRONGLY ASSOCIATED WITH ACEH3K9 (ACETYLATED HISTONE H3 LYSINE9) AFTER MORPHINE AND SAHA TREATMENT. FURTHERMORE, MORPHINE TREATMENT CAUSED AN INCREASE IN SPINAL BDNF AND DYNORPHIN LEVELS, AND THESE LEVELS WERE FURTHER INCREASED IN SAHA TREATED MICE. THE SELECTIVE TRKB (TROPOMYOSIN-RECEPTOR-KINASE) ANTAGONIST ANA-12 REDUCED OIH WHEN GIVEN ONE OR SEVEN DAYS AFTER CESSATION OF MORPHINE. TREATMENT WITH THE SELECTIVE KAPPA OPIOID RECEPTOR ANTAGONIST NOR-BNI ALSO REDUCED ESTABLISHED OIH. THE CO-ADMINISTRATION OF EITHER RECEPTOR ANTAGONIST AGENT DAILY WITH MORPHINE RESULTED IN ATTENUATION OF HYPERALGESIA PRESENT ONE DAY AFTER CESSATION OF TREATMENT. ADDITIONALLY, REPEATED MORPHINE EXPOSURE INDUCED A RISE IN BDNF EXPRESSION THAT WAS ASSOCIATED WITH AN INCREASED NUMBER OF BDNF+ CELLS IN THE SPINAL CORD DORSAL HORN, SHOWING STRONG CO-LOCALIZATION WITH ACEH3K9 IN NEURONAL CELLS. LASTLY, SPINAL APPLICATION OF LOW DOSE BDNF OR DYNORPHIN A AFTER RESOLUTION OF OIH PRODUCED MECHANICAL HYPERSENSITIVITY, WITH NO EFFECT IN CONTROLS. CONCLUSIONS: THE PRESENT STUDY IDENTIFIED TWO GENES WHOSE EXPRESSION IS REGULATED BY EPIGENETIC MECHANISMS DURING MORPHINE EXPOSURE. TREATMENTS AIMED AT PREVENTING THE ACETYLATION OF HISTONES OR BLOCKING BDNF AND DYNORPHIN SIGNALING MAY REDUCE OIH AND IMPROVE LONG-TERM PAIN USING OPIOIDS. 2014 18 1495 25 DNA HYPERMETHYLATION OF CELL CYCLE (P15 AND P16) AND APOPTOTIC (P14, P53, DAPK AND TMS1) GENES IN PERIPHERAL BLOOD OF LEUKEMIA PATIENTS. ABERRANT DNA METHYLATION OF TUMOR SUPPRESSOR GENES HAS BEEN REPORTED IN ALL MAJOR TYPES OF LEUKEMIA WITH POTENTIAL INVOLVEMENT IN THE INACTIVATION OF REGULATORY CELL CYCLE AND APOPTOSIS GENES. HOWEVER, MOST OF THE PREVIOUS REPORTS DID NOT SHOW THE EXTENT OF CONCURRENT METHYLATION OF MULTIPLE GENES IN THE FOUR LEUKEMIA TYPES. HERE, WE ANALYZED SIX KEY GENES (P14, P15, P16, P53, DAPK AND TMS1) FOR DNA METHYLATION USING METHYLATION SPECIFIC PCR TO ANALYZE PERIPHERAL BLOOD OF 78 LEUKEMIA PATIENTS (24 CML, 25 CLL, 12 AML, AND 17 ALL) AND 24 HEALTHY VOLUNTEERS. IN CML, METHYLATION WAS DETECTED FOR P15 (11%), P16 (9%), P53 (23%) AND DAPK (23%), IN CLL, P14 (25%), P15 (19%), P16 (12%), P53 (17%) AND DAPK (36%), IN AML, P14 (8%), P15 (45%), P53 (9%) AND DAPK (17%) AND IN ALL, P15 (14%), P16 (8%), AND P53 (8%). THIS STUDY HIGHLIGHTED AN ESSENTIAL ROLE OF DAPK METHYLATION IN CHRONIC LEUKEMIA IN CONTRAST TO P15 METHYLATION IN THE ACUTE CASES, WHEREAS TMS1 HYPERMETHYLATION WAS ABSENT IN ALL CASES. FURTHERMORE, HYPERMETHYLATION OF MULTIPLE GENES PER PATIENT WAS OBSERVED, WITH OBVIOUS SELECTIVENESS IN THE 9P21 CHROMOSOMAL REGION GENES (P14, P15 AND P16). INTERESTINGLY, METHYLATION OF P15 INCREASED THE RISK OF METHYLATION IN P53, AND VICE VERSA, BY FIVE FOLDS (P=0.03) INDICATING POSSIBLE SYNERGISTIC EPIGENETIC DISRUPTION OF DIFFERENT PHASES OF THE CELL CYCLE OR BETWEEN THE CELL CYCLE AND APOPTOSIS. THE INVESTIGATION OF MULTIPLE RELATIONSHIPS BETWEEN METHYLATED GENES MIGHT SHED LIGHT ON TUMOR SPECIFIC INACTIVATION OF THE CELL CYCLE AND APOPTOTIC PATHWAYS. 2014 19 2300 34 EPIGENETIC REGULATION OF BDNF EXPRESSION IN THE PRIMARY SENSORY NEURONS AFTER PERIPHERAL NERVE INJURY: IMPLICATIONS IN THE DEVELOPMENT OF NEUROPATHIC PAIN. BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) IS KNOWN TO BE UP-REGULATED IN THE DORSAL ROOT GANGLION (DRG) AFTER PERIPHERAL NERVE INJURY, AND TO CONTRIBUTE TO NEUROPATHIC PAIN. HERE, WE FOUND THAT THERMAL HYPERALGESIA AND MECHANICAL ALLODYNIA AT DAY 7 POST-INJURY WERE INHIBITED ONLY WHEN ANTI-BDNF ANTIBODY WAS INTRATHECALLY ADMINISTRATED AT DAY 2 POST-INJURY. CONSISTENT WITH BEHAVIORAL RESULTS, WESTERN BLOT ANALYSIS SHOWED THAT THE EXPRESSION LEVELS OF BDNF PROTEIN IN THE SPINAL DORSAL HORN WERE MARKEDLY INDUCED DURING EARLY STAGE POST-INJURY. MOREOVER, THE MAXIMAL INCREASE IN BDNF MRNA EXPRESSION IN THE DRG WAS OBSERVED AT DAY 1 POST-INJURY, AND SIGNIFICANTLY ELEVATED LEVELS WERE SUSTAINED FOR AT LEAST 14 DAYS. FOUR OF FIVE BDNF MRNA TRANSCRIPTS WERE UP-REGULATED AFTER NERVE INJURY, AND THE MOST INDUCIBLE TRANSCRIPT WAS EXON I. USING A CHROMATIN IMMUNOPRECIPITATION (CHIP) ASSAY, WE FOUND THAT NERVE INJURY PROMOTES HISTONE H3 AND H4 ACETYLATION, TRANSCRIPTIONALLY ACTIVE MODIFICATIONS, AT BDNF PROMOTER I AT DAY 1 POST-INJURY, AND THE LEVELS OF HISTONE ACETYLATION REMAIN ELEVATED FOR AT LEAST 7 DAYS. TAKEN TOGETHER, OUR FINDINGS SUGGEST THAT AN INITIAL INCREASE IN BDNF EXON I EXPRESSION CONTROLLED BY EPIGENETIC MECHANISMS MIGHT HAVE A CRUCIAL ROLE IN THE DEVELOPMENT OF NEUROPATHIC PAIN. 2013 20 4913 38 PAIN MODULATION IN WAG/RIJ EPILEPTIC RATS (A GENETIC MODEL OF ABSENCE EPILEPSY): EFFECTS OF BIOLOGICAL AND PHARMACOLOGICAL HISTONE DEACETYLASE INHIBITORS. EPIGENETIC MECHANISMS ARE INVOLVED IN EPILEPSY AND CHRONIC PAIN DEVELOPMENT. ABOUT THAT, WE STUDIED THE EFFECTS OF THE NATURAL HISTONE DEACETYLASE (HDAC) INHIBITOR SODIUM BUTYRATE (BUT) IN COMPARISON WITH VALPROIC ACID (VPA) IN A VALIDATED GENETIC MODEL OF GENERALIZED ABSENCE EPILEPSY AND EPILEPTOGENESIS. WAG/RIJ RATS WERE TREATED WITH BUT (30 MG/KG), VPA (300 MG/KG), AND THEIR COMBINATION (BUT + VPA) DAILY PER OS FOR 6 MONTHS. RATS WERE SUBJECTED AT RANDALL-SELITTO, VON FREY, HOT PLATE, AND TAIL FLICK TESTS AFTER 1, 3, AND 6 MONTHS OF TREATMENT TO EVALUATE HYPERSENSITIVITY TO NOXIOUS AND NON-NOXIUOUS STIMULI. MOREOVER, PPAR-GAMMA (G3335 1 MG/KG), GABA-B (CGP35348 80 MG/KG), AND OPIOID (NALOXONE 1 MG/KG) RECEPTOR ANTAGONISTS WERE ADMINISTRATED TO INVESTIGATE THE POSSIBLE MECHANISMS INVOLVED IN ANALGESIC ACTIVITY. THE EXPRESSION OF NFKB, GLUTATHIONE REDUCTASE, AND PROTEIN OXIDATION (CARBONYLATION) WAS ALSO EVALUATED BY WESTERN BLOT ANALYSIS. WAG/RIJ RATS SHOWED AN ALTERED PAIN THRESHOLD THROUGHOUT THE STUDY (P < 0.001). BUT AND BUT + VPA TREATMENT REDUCED HYPERSENSITIVITY (P < 0.01). VPA WAS SIGNIFICANTLY EFFECTIVE ONLY AFTER 1 MONTH (P < 0.01). ALL THE THREE RECEPTORS ARE INVOLVED IN BUT + VPA EFFECTS (P < 0.001). BUT AND BUT + VPA DECREASED THE EXPRESSION OF NFKB AND ENHANCED GLUTATHIONE REDUCTASE (P < 0.01); PROTEIN OXIDATION (CARBONYLATION) WAS REDUCED (P < 0.01). NO EFFECT WAS REPORTED WITH VPA. IN CONCLUSION BUT, ALONE OR IN COADMINISTRATION WITH VPA, IS A VALUABLE CANDIDATE FOR MANAGING THE EPILEPSY-RELATED PERSISTENT PAIN. 2020